New Delhi: Indian Pharma industry has assured Govt that there is no shortage of drugs and medicines in India. This assurance came in the light of media reports which claimed that shortages and potential price increases of generic drugs from India may loom if the coronavirus outbreak disrupts suppliers of pharmaceutical ingredients in China past April. Being an important supplier of generic drugs to the world, Indian companies as awhole procure almost 70% of the active pharmaceutical ingredients (APIs) for their medicines from China.
India’s generic drugmakers say they currently have enough API supplies from China to cover their operations for up to about three months.Govt and Industry in Action Mode keeping in view the country’s over dependence on import of Active Pharmaceutical Ingredients(APIs), Government of India has constituted a Task Force on APIs under the chairmanship of Minister of State for Shipping (I/C) and Chemicals & Fertilizers Mansukh Mandaviya to formulate a road map for the enhanced productionof APIs in the country.
The 5th Meeting of the Task Force was held today. Several important issues were discussedregarding policy relaxations to small, medium and large API units and alsosimplification of the process for environment clearance for production and availability of medicines .In the meeting, Mansukh Mandaviya took stock of the situation of availability of drugs and medicines.
The Industry Representatives has explained thoroughly to Mansukh Mandaviya that they have enough drugs and medicines to deal with any contingency arising outof impact of CoronaVirus. They ensured that there will be no shortage of any Drugs, APIs and Medicines in the coming days in India.During the meeting,the challenges faced by the Pharmaceutical Industry in obtaining Environment Clearance were also discussed.
The representative of Ministry of Environmentand Forest, Climate Change (MoEF&CC) has stated that steps are being takento expedite Environment Clearances and also mentioned that recently MoEF&CC has modified the guidelines so that there is no need to obtain separate Environment Clearance, if the production of the Pharma unit is increased by 50%.